New release my @OncoKB people! Major updates: Removal of FGFR2-fusion+ #bladdercancer as L1 based on @US_FDA amendmt to erdafitinib label +MDM2 amplification➡️L3A in intimal-& lipo-sarcomas based on compelling clinical activity of MDM2-p53 antag milademetan&brigimadlin resp

New @OncoKB release people! AKT1 (& PIK3CA & PTEN onc mut) = Level 1 w/ pan-AKT inh capivasertib + fulvestrant @US_FDA apprval for pts w/ breast cancer 🤔drug showed activity in overall ER+/HER2- popn +Reprotrectinib apprvd in ROS1+ NSCLC w/ activity against solvt front resist

Additional great @OncoKB news people!! In addition to the #NSCLC @NCCN Guidelines® referring to @OncoKB as a resource for ERBB2 mutations now the #UterineNeoplasms @NCCN Guidelines® hv also incl @OncoKB as a reference for BRCA mutations!!

New @OncoKB release people! We now hv "@US_FDA approved Precision Oncology Therapies" page incl year of approval, the specific drug label biomarker & method of detection KRAS G12Ci sotorasib/adagrasib+EGFR monoclonal abs cetux/panitumumab are std care level 2 by @NCCN incl

As promised here's a quick tweetorial for our @CD_AACR article: Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer bit.ly/46X72vj 👇👇👇

Better late that never -- new @OncoKB release people! Steadily increasing our gene curation &1 new @US_FDA approval of Dostarlimab + Carboplatin + Paclitaxel for MSI-H+ endometrial ca Prepping for our meeting w/ our Clinical Genomics Annotation Committee & Ext Advisory Board!

As the summer comes to an end...new @OncoKB release people! oncokb.org/news 38 new genes & 1 gene away from 800 individually curated cancer genes. These incl IgG CD19 recurrently amplified in heme B-cell malignancies & CHD2, a chromodomain helicase, freq mut in CLL

New @OncoKB release people! +14 new genes including oncogenes CDH2 & CDH4 that are members of cadherin family Also quizartinib in FLT3-ITD+ AML goes from Level 3A➡️1 w/ its @US_FDA approval Quick poll: If you were to leave X where would you go to build up medTwitter??

Massive @OncoKB release people ! Tough @US_FDA apprv of talozaparib + enzalutamide in prostate cancer: activity really only in BRCA2 mut pts but approval for 12(!) HRR genes L3A for Vorasidenib in IDH1/2 mut glioma - likely L1 soon Removal of Debio1347 due to -ve trial - impt!

When your @OncoKB @DanaFarber External Advisory Board member finds your far off booth and stops by to say hello to the team #mentorship #Mensch @VanAllenLab

2 December @OncoKB releases people! As promised, every @US_FDA targeted drug approval = an @OncoKB release Dec 13: Olutasidenib in IDH1 R132 mutant AML Dec 22: Adagrasib in KRAS G12C mut NSCLC AND wait for it… – at Manhattan, NY

@OncoKB release people & >700 cancer genes curated to date! What a great way to join our team @OncoKB scientists @AmandaDhanes & @NicoleCFern!! 👏 @ritikakundra10 too! Also stay tuned for @OncoKB releases w/every new FDA targeted drug approval or NCCN precision oncology update!

New @OncoKB release people! 7 yrs post @DHymanMD & @baselga1's BRAF V600E basket trial, BRAF V600E is now Level 1 in all solid tumors ➡️ 4th @US_FDA recognized tumor agnostic biomarker after NTRK fusions, MSI-H & TMB-H Another 1st? ERBB2 oncogenic mut are Level 1 in #lungcancer

New @OncoKB release people! -KMT2A fusions & NPM1 mut level 3A based on compelling clinical activity of menin inh in pts w/ AML -ALK fusions are FINALLY level 1 in inflammatory myofibroblastic tumors! [PS. We're hiring! bit.ly/3RYqXn1]